Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention
- Conditions
- Ventricular RemodelingMyocardial Infarction, Anterior Wall
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Target Recruit Count
- 100
- Registration Number
- NCT06463808
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Adaptions and Resiliency to Multi-Stressor OpeRations
- Conditions
- Musculoskeletal InjuryHypogonadism
- Interventions
- Other: Multi-Stressor TrainingDrug: Placebo Patch
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Bradley Nindl
- Target Recruit Count
- 120
- Registration Number
- NCT06455969
- Locations
- 🇺🇸
Neuromuscular Research Laboratory, Pittsburgh, Pennsylvania, United States
First Human Trial of Targeting MDM2/MDMX PET Imaging
- Conditions
- Positron Emission Tomography ImaingMDM2/MDMX Gene MutationNuclear Medicine
- Interventions
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 20
- Registration Number
- NCT06443762
To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Target Recruit Count
- 60
- Registration Number
- NCT06385847
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
- Conditions
- Oligometastatic Prostate CancerLocally Advanced Prostate Cancer
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Target Recruit Count
- 40
- Registration Number
- NCT06387056
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
- Conditions
- Recurrent Castration-Sensitive Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Recurrent Prostate CancerCastration-resistant Prostate Cancer
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation TherapyProcedure: Magnetic Resonance ImagingOther: Patient ObservationProcedure: Positron Emission Tomography
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 220
- Registration Number
- NCT06378866
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
- Conditions
- Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHER2-positive Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 74
- Registration Number
- NCT06348134
- Locations
- 🇳🇬
Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife, Osun, Nigeria
🇺🇸University of Chicago, Chicago, Illinois, United States
Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
- Conditions
- Prostate Cancer
- Interventions
- Radiation: RadiotherapyDrug: Depo-Eligard 45 mgDrug: Depo-Eligard 22.5 mgDrug: Depo-Eligard 7.5 mg
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Cancer Research Antwerp
- Target Recruit Count
- 493
- Registration Number
- NCT06282588
- Locations
- 🇧🇪
AZ Groeninge, Kortrijk, Belgium
🇧🇪GZA Sint-Augustinus, Wilrijk, Antwerp, Belgium
🇧🇪OLVZ Aalst, Aalst, Belgium
Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients
- Conditions
- Acute Myeloid Leukemia, Adult
- Interventions
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 20
- Registration Number
- NCT06252584
Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients
- Conditions
- Triple Negative Breast CancerPremenopausal Breast Cancer
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 124
- Registration Number
- NCT06225284
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.